Associated tags: MSD, Health, Woman, OGN, Organon, NYSE, Pharmaceutical, Biotechnology, Consumer, Women, Pharmaceutical industry, General Health
Locations: EUROPE, NEW YORK, ASIA PACIFIC, CALIFORNIA, QUEBEC, LATIN AMERICA, CARIBBEAN, VA, EU, EUROPEAN UNION, UNITED STATES, NORTH AMERICA, NEW JERSEY, II, CHINA, CANADA, BRAZIL
General Health,
Pharmaceutical,
Health,
Medical Devices,
Sale,
Person,
OGN,
European Economic Area,
Regulation,
Credit,
Note,
Security (finance) Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the “Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “Unsecured Notes” and, together with the Secured Notes the “Notes”).
Key Points:
- Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the “Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “Unsecured Notes” and, together with the Secured Notes the “Notes”).
- Each series of notes will be guaranteed by each of the entities that guarantees the Companies’ existing senior secured credit facilities (the “Credit Facilities”).
- The initial offering price to investors will be 100% of the principal amount thereof.
- The Notes offering is expected to close on May 17, 2024, subject to customary closing conditions.
Health,
Consumer,
Women,
General Health,
Pharmaceutical,
Biotechnology,
Sale,
Person,
OGN,
European Economic Area,
Regulation,
Credit,
Security (finance) Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the “secured notes”) and $500 million of senior unsecured notes due 2034 (the “unsecured notes” and, together with the Secured Notes the “notes”).
Key Points:
- Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the “secured notes”) and $500 million of senior unsecured notes due 2034 (the “unsecured notes” and, together with the Secured Notes the “notes”).
- Each series of notes will be guaranteed by each of the entities that guarantees the Companies’ existing senior secured credit facilities (the “Credit Facilities”).
- The notes offering is expected to be a leverage-neutral transaction.
- The Companies intend to use the net proceeds from the sale of the notes to repay a portion of their borrowings under the Credit Facilities’ U.S. dollar-denominated “tranche B” term loan and to pay the fees and expenses incurred in connection with the foregoing.
Women’s Health revenue increased 11% on an as-reported basis, and increased 12% ex-FX in the first quarter of 2024 compared with the first quarter of 2023 primarily driven by 34% ex-FX growth in Nexplanon® (etonogestrel implant).
Key Points:
- Women’s Health revenue increased 11% on an as-reported basis, and increased 12% ex-FX in the first quarter of 2024 compared with the first quarter of 2023 primarily driven by 34% ex-FX growth in Nexplanon® (etonogestrel implant).
- Biosimilars revenue grew 46% on an as-reported basis and 46% ex-FX in the first quarter of 2024, compared with the first quarter of 2023.
- Established Brands revenue was flat on an as-reported basis and grew 2% ex-FX in the first quarter of 2024.
- The company expects revenue growth in the Established Brands franchise to be about flat for full year 2024 on an ex-FX basis.
Research,
Women,
Clinical Trials,
Biotechnology,
Managed Care,
General Health,
Pharmaceutical,
Consumer,
Health,
Science,
Name,
Patient,
Denosumab,
BMD,
Woman,
Biosimilar,
European,
Fracture,
Osteoporosis,
Safety,
Multimedia,
OGN Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints.
Key Points:
- Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints.
- In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14.
- The agreement covers markets such as the United States, the European Union, and Canada.
- The primary endpoints of this study were met.
Biotechnology,
Women,
Consumer,
Health,
Pharmaceutical,
GAAP,
Denosumab,
ID,
Webcast,
IPR,
Uncertainty,
Research,
Biosimilar,
EDT,
OGN,
Broadcasting Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its first quarter 2024 financial results on May 2, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
Key Points:
- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its first quarter 2024 financial results on May 2, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
- Organon currently expects that it will record approximately $15 million of milestone payments in the first quarter of 2024, representing approximately $0.05 to both GAAP and non-GAAP earnings per share.
- Organon’s first quarter 2024 results have not been finalized and are subject to the company’s quarterly financial statement closing procedures.
- Accessing First Quarter 2024 Financial Results Webcast:
Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
Retrieved on:
Tuesday, February 20, 2024
FDA,
Health,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Certification,
Sepsis,
Psoriasis,
Adolescence,
Infection,
Adalimumab,
Hospital,
Intuition,
Public sector,
TB,
Risk,
Safety,
Arthritis,
Rheumatoid arthritis,
Hidradenitis suppurativa,
Death,
Autoimmunity,
Patient,
Lymphoma,
Tuberculosis,
Malignancy,
TNF,
OGN,
Pharmaceutical industry Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
Key Points:
- Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
- "America’s veterans deserve access to quality medicines at a lower cost.
- “We applaud the VA for its leadership in championing biosimilars and including all three of Organon’s biosimilars available in the US on its formulary."
- HADLIMA was launched in the US to offer patients a more affordable option without compromising on safety and efficacy.
Woman,
Workplace,
Health,
Female,
Endometriosis,
Menstruation,
World Bank,
Fertility,
Menopause,
Head,
Organization,
Statistics,
Movement,
Workforce,
HER,
International Women's Day,
Nursing This International Women's Day, the company is excited to announce the launch of HER Professional Journey, an initiative designed to overcome these challenges while empowering all employees to navigate their career paths confidently.
Key Points:
- This International Women's Day, the company is excited to announce the launch of HER Professional Journey, an initiative designed to overcome these challenges while empowering all employees to navigate their career paths confidently.
- "At Organon Canada, we work to create a healthier future for women and their families," said Michael Casia, President and Managing Director at Organon Canada.
- Organon Canada believes that not only is investing in women's careers the right thing to do, but also that keeping women in the workplace is good for business.
- Organon Canada is encouraging other organizations to join in the movement and Invest In HER, so that women are supported throughout their career journeys.
Retrieved on:
Thursday, February 15, 2024
Biotechnology,
Women,
Consumer,
Health,
Pharmaceutical,
Desogestrel,
Merck,
Ezetimibe,
Losartan,
Growth,
Adalimumab,
Atorvastatin,
Calcium,
Fertility,
Etonogestrel,
Gonadotropin preparations,
Interim,
COVID-19,
Merck & Co.,
VBP,
Patient,
Video game For the fourth quarter of 2023, total revenue was $1,598 million, an increase of 8% on an as-reported basis as well as excluding impact of foreign currency (ex-FX), compared with the fourth quarter of 2022.
Key Points:
- For the fourth quarter of 2023, total revenue was $1,598 million, an increase of 8% on an as-reported basis as well as excluding impact of foreign currency (ex-FX), compared with the fourth quarter of 2022.
- Women’s Health revenue increased 7% on an as-reported basis, and increased 8% ex-FX in the fourth quarter of 2023 compared with the fourth quarter of 2022 driven primarily by strong growth in the company's fertility products, particularly Follistim AQ® (follitropin beta injection).
- Revenue of Hadlima™ (adalimumab-bwwd) more than doubled in the fourth quarter of 2023 compared with the fourth quarter of 2022 as a result of continued uptake since its July 2023 launch in the U.S.
- Established Brands revenue increased 3% as-reported and 3% ex-FX in the fourth quarter of 2023 despite the impacts of Volume Based Procurement (VBP) initiatives and a challenging operating environment in China.
Retrieved on:
Thursday, February 1, 2024
Women,
Biotechnology,
Pharmaceutical,
Managed Care,
General Health,
Health,
Consumer,
Other Health,
OGN,
EST,
Interest,
Webcast,
ID Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2023 financial results on February 15, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
Key Points:
- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2023 financial results on February 15, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
- Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
- A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
- Pre-registration will allow participants to bypass an operator and be placed directly into the call.
Retrieved on:
Wednesday, January 10, 2024
Health,
Consumer,
Women,
General Health,
Pharmaceutical,
Biotechnology,
CDAD,
Development,
Woman,
Hydrogen chloride,
Hypersensitivity,
Patient,
OGN,
Frustration,
Thermoregulation,
Gynaecology,
History,
Bacterial vaginosis,
Clostridioides,
Environment,
Recurrence,
Research and development,
BV,
Bacteria,
Clindamycin,
Lincomycin,
Infection,
American College Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
Key Points:
- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
- Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
- If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.
- Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com .
